What is the price-to-earnings ratio of Evotec?
The price-earnings ratio of Evotec is currently 1.96.
Evotec P/S 2024
Evotec P/S
1.96
Ticker
EVT.DE
ISIN
DE0005664809
WKN
566480
As of Dec 30, 2024, Evotec's P/S ratio stood at 1.96, a -58.56% change from the 4.73 P/S ratio recorded in the previous year.
The Evotec P/S history
Evotec Aktienanalyse
What does Evotec do?
Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Evotec's P/S Ratio
Evotec's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Evotec's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Evotec's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Evotec’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Evotec stock
How has the price-earnings ratio of Evotec changed compared to last year?
The price-to-earnings ratio of Evotec has increased by -58.56% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Evotec high compared to other companies?
Yes, the price-to-earnings ratio of Evotec is high compared to other companies.
How does an increase in the price-earnings ratio of Evotec affect the company?
An increase in the price-earnings ratio of Evotec would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Evotec affect the company?
A decrease in the price-earnings ratio of Evotec would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Evotec?
Some factors that influence the price-earnings ratio of Evotec are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Evotec pay?
Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.
What is the dividend yield of Evotec?
The current dividend yield of Evotec is .
When does Evotec pay dividends?
Evotec pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Evotec?
Evotec paid dividends every year for the past 0 years.
What is the dividend of Evotec?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Evotec located?
Evotec is assigned to the 'Health' sector.
Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Evotec from 12/30/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/30/2024.
When did Evotec pay the last dividend?
The last dividend was paid out on 12/30/2024.
What was the dividend of Evotec in the year 2023?
In the year 2023, Evotec distributed 0 EUR as dividends.
In which currency does Evotec pay out the dividend?
The dividends of Evotec are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Andere Kennzahlen von Evotec
Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
